Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Because the price of the Rehart drug has not been determined and revenue is difficult to estimate, the company estimated profit and loss at each stage without factoring in revenue or cost of sales. The company plans to disclose a revenue forecast and revise its consolidated earnings forecast once the drug price becomes clear.
| Item | Details |
|---|---|
| Operating profit | Not disclosed → ¥-1,430 million |
| Ordinary income | Not disclosed → ¥-1,400 million |
| Profit attributable to owners of the parent | Not disclosed → ¥-1,390 million |
| Net income per share | Not disclosed → -168.33 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Revenue ¥212 million, operating loss ¥1,081 million, ordinary loss ¥1,028 million, net loss attributable to owners of the parent ¥1,022 million, net loss per share ¥124.54 |
| Reason for the revision | Because the price of the Rehart drug has not been determined and revenue is difficult to estimate, the company estimated profit and loss at each stage without factoring in revenue or cost of sales. The company plans to disclose a revenue forecast and revise its consolidated earnings forecast once the drug price becomes clear. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because the price of the Rehart drug has not been determined and revenue is difficult to estimate, the company estimated profit and loss at each stage without factoring in revenue or cost of sales. The company plans to disclose a revenue forecast and revise its consolidated earnings forecast once the drug price becomes clear.